Factors contributing to the systemic clearance of infliximab with long-term administration in Japanese patients with Crohn’s disease: Analysis using population pharmacokinetics-Reference-Cited by-同舟云学术

Factors contributing to the systemic clearance of infliximab with long-term administration in Japanese patients with Crohn’s disease: Analysis using population pharmacokinetics

Published:2020-02-01 Issue:02 Volume:58 Page:89-102
ISSN:0946-1965
Container-title:Int. Journal of Clinical Pharmacology and Therapeutics
language:en
Short-container-title:CP

Author:

Matsuoka Katsuyoshi,Hamada Shunsuke,Shimizu Mikiko,Nanki Kosaku,Mizuno Shinta,Kiyohara Hiroki,Arai Mari,Sugimoto Shinya,Iwao Yasushi,Ogata Haruhiko,Hisamatsu Tadakazu,Nagauma Makoto,Kanai Takanori,Mochizuki Mayumi,Hashiguchi Masayuki

Publisher

Dustri-Verlgag Dr. Karl Feistle

Subject

Pharmacology (medical),Pharmacology

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease;Frontiers in Pharmacology;2024-08-27

2. The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease Patients;Journal of Crohn's and Colitis;2024-01-19

3. Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics;Journal of Clinical Medicine;2023-11-16

4. Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review;Pharmaceutics;2023-02-25

5. Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases;CPT: Pharmacometrics & Systems Pharmacology;2022-06-15